Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Opinion CV Team Dispatch

May 2023 News Roundup

L.A. McKeown

May 01, 2023

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

More Evidence Links Breast Arterial Calcification and CVD Risk

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Daily News

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

Caitlin E. Cox

March 24, 2021

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Conference News ACC 2017

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Shelley Wood

March 09, 2017

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Todd Neale

February 08, 2017

News Daily News

Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery

Todd Neale

February 25, 2016

Advertisement

September 2025 Dispatch for the CV Team

September 2024 Dispatch for the CV Team

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

May 2024 Dispatch for the CV Team

Biologic Winrevair Wins FDA Approval for Treatment of PAH

March 2024 Dispatch for the CV Team

Top Endovascular News of 2023

May 2023 News Roundup

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

More Evidence Links Breast Arterial Calcification and CVD Risk

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content